1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Dyskinesia Syndromes in 32 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| "Hydrogen sulfide (H(2)S) has been shown to protect neurons." | 1.37 | Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. ( Ichinose, F; Kakinohana, M; Kaneki, M; Kida, K; Marutani, E; Tokuda, K; Yamada, M, 2011) |
| "Pre-treatment with benserazide for up to 3h did not alter the motor response to L-DOPA compared to simultaneous administration with L-DOPA." | 1.36 | The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. ( Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G, 2010) |
| " However, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements." | 1.36 | The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. ( Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K, 2010) |
| "The common marmoset develops motor deficits after MPTP treatment and exhibits dyskinesia after chronic levodopa (L-dopa) dosing and subsequent re-challenge with L-dopa and other dopaminergic agents." | 1.31 | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. ( Banerji, T; Jackson, MJ; Jenner, P; Pearce, RK; Scheel-Krüger, J; Smith, LA, 2002) |
| "Pretreatment with entacapone (12." | 1.30 | Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. ( Gordin, A; Jenner, P; Marsden, CD; Smith, LA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (43.75) | 18.7374 |
| 1990's | 9 (28.13) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 4 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Wei, Z | 1 |
| Li, H | 1 |
| Zhou, H | 1 |
| Zhang, Z | 2 |
| Tayarani-Binazir, KA | 1 |
| Jackson, MJ | 4 |
| Fisher, R | 1 |
| Zoubiane, G | 1 |
| Rose, S | 2 |
| Jenner, P | 5 |
| Tayarani-Binazir, K | 1 |
| McCreary, AC | 1 |
| Kida, K | 1 |
| Yamada, M | 1 |
| Tokuda, K | 1 |
| Marutani, E | 1 |
| Kakinohana, M | 1 |
| Kaneki, M | 1 |
| Ichinose, F | 1 |
| Huot, P | 1 |
| Johnston, TH | 1 |
| Gandy, MN | 1 |
| Reyes, MG | 1 |
| Fox, SH | 1 |
| Piggott, MJ | 1 |
| Brotchie, JM | 1 |
| Pearce, RK | 1 |
| Smith, LA | 2 |
| Banerji, T | 1 |
| Scheel-Krüger, J | 1 |
| Linazasoro, G | 1 |
| Haobam, R | 1 |
| Sindhu, KM | 1 |
| Chandra, G | 1 |
| Mohanakumar, KP | 1 |
| Iravani, MM | 1 |
| Costa, S | 1 |
| Al-Bargouthy, G | 1 |
| Zeng, BY | 1 |
| Kuoppamäki, M | 1 |
| Obeso, JA | 2 |
| Tatton, WG | 1 |
| Eastman, MJ | 1 |
| Bedingham, W | 1 |
| Verrier, MC | 1 |
| Bruce, IC | 1 |
| Langston, JW | 1 |
| Ballard, P | 1 |
| Cardoso, F | 1 |
| Jankovic, J | 1 |
| Yoshida, M | 1 |
| Wichmann, T | 1 |
| DeLong, MR | 2 |
| Lopez, W | 1 |
| Jeste, DV | 1 |
| Guridi, J | 1 |
| Gordin, A | 1 |
| Marsden, CD | 3 |
| Morissette, M | 1 |
| Grondin, R | 2 |
| Goulet, M | 1 |
| Bédard, PJ | 3 |
| Di Paolo, T | 2 |
| Doan, VD | 1 |
| Grégoire, L | 1 |
| Bradbury, AJ | 2 |
| Costall, B | 2 |
| Domeney, AM | 2 |
| Testa, B | 1 |
| Jenner, PG | 1 |
| Naylor, RJ | 2 |
| Jenner, PJ | 1 |
| Schultz, W | 2 |
| Scarnati, E | 2 |
| Sundström, E | 2 |
| Romo, R | 2 |
| Studer, A | 1 |
| Jonsson, G | 1 |
| Clarke, CE | 2 |
| Boyce, S | 2 |
| Robertson, RG | 2 |
| Sambrook, MA | 2 |
| Crossman, AR | 2 |
| Weihmuller, FB | 1 |
| Hadjiconstantinou, M | 1 |
| Bruno, JP | 1 |
| Neff, NH | 1 |
| Doudet, D | 1 |
| Gross, C | 1 |
| Lebrun-Grandié, P | 1 |
| Bioulac, B | 1 |
| Schneider, JS | 1 |
| Unguez, G | 1 |
| Yuwiler, A | 1 |
| Berg, SC | 1 |
| Markham, CH | 1 |
| Falardeau, P | 1 |
| Boucher, R | 1 |
| Willis, GL | 1 |
| Savulescu, J | 1 |
| Horne, MK | 1 |
| Smith, GC | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| TMS Measures in Parkinson's Disease[NCT00023062] | 80 participants | Observational | 2001-08-31 | Completed | |||
| Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.[NCT00228371] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to insufficent enrolement) | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Deep Brain Stimulation Surgery for Movement Disorders[NCT01581580] | 200 participants (Anticipated) | Interventional | 2011-08-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia Syndromes
| Article | Year |
|---|---|
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
Movement disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Amphetamines; Cocaine; Dyskinesia, Drug-In | 1993 |
Pathophysiology of parkinsonian motor abnormalities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Cerebral Cortex | 1993 |
Movement disorders and substance abuse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Central Nervous System Stimulants; Drug In | 1997 |
The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Functional Laterality; Haplo | 1997 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levo | 1987 |
25 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia Syndromes
| Article | Year |
|---|---|
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Di | 2009 |
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; | 2010 |
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Benzoxazoles; Callithrix; D | 2010 |
Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Inhalation; Animals; Apoptosis; Base S | 2011 |
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodioxoles; Biogenic Monoamines; Callithri | 2012 |
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disability Evaluation; Dopamine A | 2002 |
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2005 |
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug | 2005 |
Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson's disease: a hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Cats; Humans; Mechanorecep | 1984 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucina | 1984 |
The neuronal mechanism underlying parkinsonism and dyskinesia, and differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bicuculline; Cats; Caudate Nucle | 1993 |
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Catechols; Dopamine Ag | 1997 |
Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Brain Chemist | 1999 |
D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Female; Levodopa; Locomotio | 1999 |
The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1985 |
The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1986 |
Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Female; Macaca fascicularis; | 1989 |
Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Corpus Striatum; Dopamine; Female; Macac | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug | 1989 |
Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Corpu | 1988 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, | 1985 |
Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Chromatography, High P | 1988 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; | 1986 |
MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Dose-Response Relation | 1987 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |